Skip to main content
Caplight Logo









DotBio

DotBio

Private
SingaporeHealthcare & Life Scienceshttps://dotbio.com/

Last Round

Early Funding

Aug 7, 2023

Total Funding Raised

$8.45M

Company Overview

DotBio is a biotechnology company that develops multi-functional and intracellular antibody therapies for immuno-oncology and other therapeutic areas using its proprietary DotBody modular platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

antibody discoveryimmuno-oncologybiotech platformmulti-specific antibodiesintracellular antibodiesdrug discoveryprotein engineeringantibody therapeuticsdrug developmentbiologicsin silico drug designAI drug discoveryantibody pipelinepharma partneringbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DotBio Comparables

Compare DotBio with similar companies based on industry and business-model similarity.

DotBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aarvik Therapeutics
83%
Crescendo Biologics Ltd.
82%
Chantibody Therapeutics
79%

DotBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingAug 7, 2023
GrantOct 23, 2020
Corporate FundingSep 15, 2020
SeedJul 30, 2018

Key People

Founding team and executive leadership

Ignacio Asial

Founder, CEO

Founding Team

Kelly Hew

Chief Operating Officer

Executive Team

DotBio Investors

Notable investors and investment history

DotBio investors
InvestorRounds
Startup SGGrant
NTUitiveSeed
National Foundation for Cancer ResearchEarly Funding
Gaorong CapitalEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 7, 2023

    $5.6M raised led by Gaorong Capital and aim-hiaccelerator.

  • Jul 30, 2018

    $2.3M raised from ASLAN Pharmaceuticals and NTUitive.

DotBio Filings

Explore SEC and related filing metadata, where available.

DotBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DotBio's valuation, stock price, and market status.

Is DotBio a public or private company?

DotBio is a private company.

What is the current stock price of DotBio?

DotBio is a private company with no public stock price. No recent secondary market data is available.

How much is DotBio worth (valuation)?

Valuation information for DotBio is not publicly available.

Can I buy DotBio stock?

DotBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DotBio's last funding round?

DotBio's most recent funding round was Early Funding on July 26, 2023.

Who are the main investors in DotBio?

Key investors in DotBio include Gaorong Capital.

Will DotBio IPO soon?

No public IPO plans have been announced for DotBio.

How can I track DotBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DotBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSingapore
Employee Range20
Year Founded2018
Last FundingAug 7, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?